ZA200203312B - Vasopressin antagonist formulation and process. - Google Patents

Vasopressin antagonist formulation and process.

Info

Publication number
ZA200203312B
ZA200203312B ZA200203312A ZA200203312A ZA200203312B ZA 200203312 B ZA200203312 B ZA 200203312B ZA 200203312 A ZA200203312 A ZA 200203312A ZA 200203312 A ZA200203312 A ZA 200203312A ZA 200203312 B ZA200203312 B ZA 200203312B
Authority
ZA
South Africa
Prior art keywords
vasopressin antagonist
antagonist formulation
formulation
vasopressin
antagonist
Prior art date
Application number
ZA200203312A
Other languages
English (en)
Inventor
Joseph Kyuwung Yoon
Mahdi Bakir Fawzi
Richard William Saunders
Original Assignee
American Cyanamid Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American Cyanamid Co filed Critical American Cyanamid Co
Publication of ZA200203312B publication Critical patent/ZA200203312B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ZA200203312A 1999-09-27 2002-04-25 Vasopressin antagonist formulation and process. ZA200203312B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US40577299A 1999-09-27 1999-09-27

Publications (1)

Publication Number Publication Date
ZA200203312B true ZA200203312B (en) 2003-12-31

Family

ID=23605168

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200203312A ZA200203312B (en) 1999-09-27 2002-04-25 Vasopressin antagonist formulation and process.

Country Status (18)

Country Link
EP (1) EP1216033A1 (ru)
JP (1) JP2003510269A (ru)
KR (1) KR20020039354A (ru)
CN (1) CN1391466A (ru)
AR (1) AR025780A1 (ru)
AU (1) AU7615000A (ru)
BR (1) BR0014351A (ru)
CA (1) CA2388474A1 (ru)
CZ (1) CZ20021083A3 (ru)
EA (1) EA200200414A1 (ru)
HK (1) HK1045109A1 (ru)
HU (1) HUP0202972A3 (ru)
IL (1) IL148541A0 (ru)
MX (1) MXPA02003189A (ru)
NO (1) NO20021475L (ru)
PL (1) PL354282A1 (ru)
WO (1) WO2001022945A1 (ru)
ZA (1) ZA200203312B (ru)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030105144A1 (en) * 2001-04-17 2003-06-05 Ping Gao Stabilized oral pharmaceutical composition
AU2003211267A1 (en) * 2002-02-27 2003-09-09 Shionogi And Co., Ltd. Solid preparations with improved absorbability of hardly water-soluble drug
JP5873375B2 (ja) * 2012-04-03 2016-03-01 中日本カプセル 株式会社 ソフトカプセル及びソフトカプセルの製造方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5516774A (en) * 1993-07-29 1996-05-14 American Cyanamid Company Tricyclic diazepine vasopressin antagonists and oxytocin antagonists
CA2318128C (en) * 1998-01-20 2008-10-14 Applied Analytical Industries, Inc. Oral liquid compositions

Also Published As

Publication number Publication date
CZ20021083A3 (cs) 2002-06-12
KR20020039354A (ko) 2002-05-25
CN1391466A (zh) 2003-01-15
NO20021475D0 (no) 2002-03-25
AR025780A1 (es) 2002-12-11
AU7615000A (en) 2001-04-30
IL148541A0 (en) 2002-09-12
HUP0202972A3 (en) 2003-07-28
EA200200414A1 (ru) 2002-12-26
CA2388474A1 (en) 2001-04-05
NO20021475L (no) 2002-04-16
HK1045109A1 (zh) 2002-11-15
MXPA02003189A (es) 2002-09-30
WO2001022945A1 (en) 2001-04-05
JP2003510269A (ja) 2003-03-18
BR0014351A (pt) 2002-06-11
PL354282A1 (en) 2003-12-29
HUP0202972A2 (hu) 2002-12-28
EP1216033A1 (en) 2002-06-26

Similar Documents

Publication Publication Date Title
MXPA02000725A (es) Formulacion opioide de liberacion sostenida.
ZA200203367B (en) Antidiabetic formulation and method.
HUP0201489A3 (en) New formulation
ZA200110022B (en) Thiazoloderivatives and pharmaceutical compositions containing them.
EG24226A (en) Formulation
EP1210084A4 (en) PYRIDOMORPHINANS, THIENOMORPHINANS AND THEIR USE
GB9905898D0 (en) Controlled-dose formulation
GB9902304D0 (en) Formulation
PL366067A1 (en) Oxayolidinone tablet formulation
ZA200203312B (en) Vasopressin antagonist formulation and process.
AU7615200A (en) Vasopressin agonist formulation and process
GB9909154D0 (en) Pharmaceutical formulation
GB9927614D0 (en) Sterliant formulation
GB9926251D0 (en) Pharmaceutical formulation
GB9902236D0 (en) Formulation
GB9923538D0 (en) Formulation
GB9915584D0 (en) Formulation
GB9908776D0 (en) Formulation
GB9917952D0 (en) Formulation
GB9902089D0 (en) Formulation
ZA200109556B (en) Pharmaceutical compositions and uses.
GB9919060D0 (en) Combination formulation
EG22401A (en) Set 3c1-strong
AU7615100A (en) Vasopressin antagonist and diuretic combination
ZA200001988B (en) Dishwashing process and compositions relating thereto.